Shaji Kumar, MD is a Professor of Medicine and Consultant in the Division of Hematology, Department of Internal Medicine at Mayo Clinic in Rochester, Minnesota, where he also serves as Research Chair of the Division of Hematology. He holds the Mark and Judy Mullins Professorship in Hematologic Malignancies and leads the Cancer Risk Assessment, Early Detection and Interception Research Program at the Mayo Clinic Comprehensive Cancer Center. Shaji Kumar, MD earned his medical degree from the All-India Institute of Medical Sciences, where he also completed his internship and internal medicine residency training. He subsequently completed a senior residency in Medical Oncology at the Institute Rotary Cancer Hospital at All-India Institute of Medical Sciences before pursuing clinical residency training in Internal Medicine at Mayo Clinic College of Medicine, followed by a fellowship in Hematology and Oncology at Mayo Graduate School of Medicine. He further trained as a Research Associate and Mayo Foundation Scholar in Multiple Myeloma at the Dana-Farber Cancer Institute/Harvard Cancer Center. Shaji Kumar, MD's research focuses on the development of novel therapeutic strategies for multiple myeloma and related plasma cell disorders, including smoldering multiple myeloma. His work spans laboratory-based drug evaluation, early-phase clinical trials, and translational investigations into the bone marrow microenvironment and its role in myeloma progression. A central focus of his research is identifying patients with smoldering myeloma who are at highest risk of progression to active disease and defining the optimal timing and intensity of early intervention in this population. He conducts NIH-funded research on novel therapeutic targets and cereblon pathway biology in myeloma, receives funding from the Multiple Myeloma Research Foundation to study the relationship between molecular profiles and treatment outcomes, and leads National Cancer Institute-funded investigations into the prevalence and biomarkers for progression of monoclonal gammopathies. In addition to his research, Shaji Kumar, MD is a widely recognized leader in the field of hematologic malignancies. He serves as Associate Editor of the American Journal of Hematology and holds editorial advisory board positions with The Lancet Haematology, Leukemia, Clinical Oncology News, and Advances in Therapy, among others. In 2024, he received the Robert A. Kyle Lifetime Achievement Award from the International Myeloma Foundation, one of the most distinguished honors in the myeloma field, and was recognized with both the Decentralized Clinical Trial Award and the Interventional-Treatment Clinical Trial Award from the Mayo Clinic Comprehensive Cancer Center.

Karl E. Anderson, MD is a graduate of the Johns Hopkins University School of Medicine. He completed his residency training in internal medicine and postgraduate training in gastroenterology at Vanderbilt University Hospital and New York Hospital Cornell Medical Center. Prior to joining the University of Texas Medical Branch in 1987, Dr. Anderson held faculty appointments at the Rockefeller University, Cornell University Medical College, and New York Medical College. He is currently a Professor in the Departments of Preventive Medicine and Community Health and Internal Medicine within the Division of Gastroenterology and Hepatology. He is also a member of the Institute for Translational Sciences and the Academy of Research Mentors. Dr. Anderson serves as Director of the Clinical Science Program in the Graduate School of Biomedical Sciences and is an active clinical investigator on the Institute for Translational Sciences Clinical Research Center, where he also holds the role of Associate Director. His research program is supported by the NIH, FDA, foundations, and industry partners. Internationally recognized for his work in the human porphyrias, Dr. Anderson's research and clinical expertise focus on the diagnosis, pathophysiology, and treatment of porphyria disorders, including acute intermittent porphyria. Through his leadership in translational research and clinical investigation, he has played a pivotal role in advancing evidence based therapies and improving care for patients with rare metabolic and hematologic conditions.

Catherine Broome, MD is a Professor of Medicine in the Division of Hematology/Oncology at MedStar Georgetown University Hospital in Washington, DC. She is board-certified in internal medicine, hematology, and medical oncology. Catherine Broome, MD has been on staff at the Georgetown Lombardi Comprehensive Cancer Center for over a decade, where she specializes in benign hematology. Her clinical expertise encompasses a range of hematologic disorders, including immune thrombocytopenia (ITP), autoimmune hemolytic anemia, cold agglutinin disease, hemophagocytic lymphohistiocytosis, paroxysmal nocturnal hemoglobinuria (PNH), and pure red cell aplasia. Catherine Broome, MD is actively involved in clinical research and offers patients the opportunity to participate in clinical trials for various hematologic conditions. In addition to her clinical work, Catherine Broome, MD serves as an associate professor in the Department of Medicine at Georgetown University, contributing to the education and training of future physicians. She also participates in the hospital's safety committee, focusing on developing programs and policies to ensure patient safety throughout MedStar Health. Catherine Broome, MD's approach to patient care emphasizes collaboration, providing patients with the most up-to-date information and treatment options, and developing personalized treatment plans that consider all aspects of the patient's life.